Brief: Hanall Biopharma Announces Results From Phase III Randomized, Double-Masked Active Treatment-Controlled Velos-3 Trial Evaluating Tanfanercept 0.25% For Treatment Of Dry Eye Disease

Hanall Biopharma

19/05/2023 12:04

May 19 (Reuters) - Hanall Biopharma Co Ltd  009420.KS :
    * HANALL BIOPHARMA ANNOUNCES RESULTS FROM PHASE III
RANDOMIZED,
DOUBLE-MASKED ACTIVE TREATMENT-CONTROLLED VELOS-3 TRIAL
EVALUATING TANFANERCEPT 0.25% FOR TREATMENT OF DRY EYE DISEASE
    * HANALL BIOPHARMA - WILL CONTINUE TO EXAMINE VELOS-3 DATA
AS WELL
AS AGGREGATE DATA ACROSS ALL TANFANERCEPT TRIALS TO REFINE
DESIGN FOR NEXT STUDY
    * HANALL BIOPHARMA CO LTD- TANFANERCEPT DID NOT DEMONSTRATE
STATISTICAL SIGNIFICANCE IN EITHER OF PRIMARY OUTCOME MEASURES
OF IMPROVEMENT IN CCSS OR EDS
    * HANALL BIOPHARMA CO - TANFANERCEPT DID DEMONSTRATE
STATISTICALLY
SIGNIFICANT IMPROVEMENT ON ONE OF SECONDARY OUTCOME MEASURES
    * HANALL BIOPHARMA - TANFANERCEPT WAS WELL TOLERATED AND
SAFETY
FINDINGS FROM VELOS-3 WERE CONSISTENT WITH THOSE OF PREVIOUS
STUDIES

Source text for Eikon:  ID:nPn8R18yta 
Further company coverage:  009420.KS